Business Context and Reporting Period
This Form 8-K Current Report was filed by Proteon Therapeutics, Inc. (referred to as "Protara Therapeutics, Inc." in the request metadata) on June 11, 2018, regarding events occurring on June 8, 2018. The company is incorporated in Delaware and is designated as an emerging growth company. The report details the results of the company's annual meeting of stockholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, there is no data provided regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing reports the outcomes of two specific proposals voted upon by stockholders at the annual meeting:
- Election of Directors: Stockholders elected all three nominees for the board of directors.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst and Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting results.
Investor Verification Checklist
- Board Composition: Verify the election of Timothy P. Noyes, Garen Bohlin, and John G. Freund, M.D. to the board of directors.
- Auditor Appointment: Confirm the ratification of Ernst and Young LLP as the independent auditor for the 2018 fiscal year.
- Voting Statistics: Note that while all directors were elected, there were significant broker non-votes (approx. 4.45 million shares) for the director election proposal.
- Company Name: Verify the registrant's legal name is "Proteon Therapeutics, Inc." as stated in the charter, despite the metadata reference to "Protara Therapeutics, Inc."